CA Patent

CA2642368A1 — Treatment of prevention of valvular heart disease with flibanserin

Assigned to Boehringer Ingelheim International GmbH · Expires 2007-09-07 · 19y expired

What this patent protects

The invention relates to a method for the treatment or prevention of Valvular Heart Disease comprising the administration of a therapeutically effective amount of flibanserin.

USPTO Abstract

The invention relates to a method for the treatment or prevention of Valvular Heart Disease comprising the administration of a therapeutically effective amount of flibanserin.

Drugs covered by this patent

Patent Metadata

Patent number
CA2642368A1
Jurisdiction
CA
Classification
—
Expires
2007-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.